Hogan Lovells is selected for Novartis Preferred Firm Program
Washington D.C.,13 February 2020 – Hogan Lovells is pleased to announce that it has been selected for the newly adopted Novartis Preferred Firm Panel 3.0. We have pledged to meet the specific diverse staffing commitments as described in Novartis’ press release. We are honored that Novartis has chosen us for the newly adopted Novartis Preferred Firm Panel 3.0, marking our inclusion as a Novartis panel firm for 11 years in a row.
After working with Novartis for over 20 years, we equally understand the moral and strategic importance of diversity and inclusion for developing talent as well as driving innovation. Our firm is committed to being a leader in diversity and inclusion, and our continued partnership with Novartis reflects these efforts. Over the past year, we have provided regulatory advice, advised them on multiple transactions as well as privacy, antitrust, IP and litigation matters. Our teams ranged from a diversity percentage of 25 to 100 percent on all of these matters, and we hope to enhance these efforts again this year.
“We are confident that Hogan Lovells can meet and exceed the Panel 3.0 staffing requirements as they are aligned with our own strategy to provide better client experiences through diverse and inclusive teams,” said Alice Valder Curran, head of Hogan Lovells Global Regulatory Practice.